SCHEMBL25849286

SCHEMBL25849286

CC1CCN(c2ccc(CNC(=O)c3ccc(S(C)(=O)=O)s3)cc2)C1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F10 P00742 3/20 0.40
ALDH1A1 P00352 2/20 0.40
LMNA P02545 2/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
HRH1 P35367 1/20 0.40
CCR3 P51677 1/20 0.40
KDM4E B2RXH2 1/20 0.39
MAPK1 P28482 1/20 0.39
RAB9A P51151 1/20 0.39
CRHBP P24387 2/20 0.39
CRHR2 Q13324 2/20 0.39
DRD2 P14416 2/20 0.38
HTR2A P28223 2/20 0.38
DRD3 P35462 2/20 0.38
TRPV1 Q8NER1 1/20 0.38
USP5 P45974 1/20 0.38
POLB P06746 1/20 0.38
HPGD P15428 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25307432 0.85 HDAC3 (0.47) F10SMN1; SMN2HRH1CCR3CRHBP
SCHEMBL25848826 0.78 USP5 (0.47) ALDH1A1LMNAHRH1CCR3KDM4E
SCHEMBL25848839 0.76 ALDH1A1 (0.49) ALDH1A1LMNASMN1; SMN2KDM4EHPGD
SCHEMBL24196149 0.74 HDAC3 (0.44) ALDH1A1SMN1; SMN2HRH1CCR3KDM4E
SCHEMBL25304254 0.74 HDAC3 (0.45) F10SMN1; SMN2CRHBPCRHR2MEN1
SCHEMBL25848823 0.73 EPHX2 (0.61) LMNARAB9AMEN1KMT2A
SCHEMBL25848811 0.73 SMN1; SMN2 (0.51) ALDH1A1SMN1; SMN2HRH1CCR3KDM4E
SCHEMBL25848935 0.73 HDAC3 (0.43) F10ALDH1A1SMN1; SMN2KDM4ECRHBP
SCHEMBL25848829 0.73 HDAC3 (0.40) ALDH1A1KDM4EKMT2A
SCHEMBL25848940 0.72 LSS (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219921-A1 KCNT1 INHIBITORS AND METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219921-A1 KCNT1 INHIBITORS AND METHODS OF USE KCNT1, KCNT2, KCNQ2 F10 4277/4885ALDH1A1 2052/4885LMNA 1423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.